Reliable high-throughput method for inhibition assay of 8 cytochrome P450 isoforms using cocktail of probe substrates and stable isotope-labeled internal standards

Drug Metabolism and Pharmacokinetics

Volumn 27, Issue 5, 2012, Pages 520-529

  Kozakai, Kazumasa ^a   Yamada, Yasuhiro ^a   Oshikata, Motoji ^b   Kawase, Taiji ^b   Suzuki, Etsuko ^b   Haramaki, Yukari ^b   Taniguchi, Hideki ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b Environmental Solution Center   (Japan)

Author keywords

Cocktail; CYP inhibition; Drug drug interaction; High throughput; Stable isotope labeled internal standard; UPLCMS MS

Indexed keywords

4' HYDROXYDICLOFENAC; 4' HYDROXYMEPHENYTOIN; 6BETA HYDROXYTESTOSTERONE; ALPHA HYDROXYMIDAZOLAM; AMFEBUTAMONE; AMODIAQUINE; BUFURALOL; COUMARIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DEETHYLAMODIAQUINE; DICLOFENAC; DICLOFENAC DERIVATIVE; MEPHENYTOIN; MIDAZOLAM; PARACETAMOL; PHENACETIN; RADAFAXINE; TESTOSTERONE; TESTOSTERONE DERIVATIVE; UMBELLIFERONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG ISOLATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; ISOTOPE LABELING; LIVER MICROSOME; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 84869119884     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-12-RG-014     Document Type: Article

References (29)

1. Monahan, B. P., Ferguson, C. L., Killeavy, E. S., Lloyd, B. K., Troy, J. and Cantilena, L. R., Jr.: Torsades de pointes occurring in association with terfenadine use. JAMA, 264: 2788-2790 (1990).
2. Honig, P. K., Wortham, D. C., Zamani, K., Conner, D. P., Mullin, J. C. and Cantilena, L. R.: Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA, 269: 1513-1518 (1993).
3. Desager, J. P. and Horsmans, Y.: Pharmacokinetic-pharmacodynamic relationships of H1-antihistamines. Clin. Pharmacokinet., 28: 419-432 (1995).
4. Wysowski, D. K. and Bacsanyi, J.: Cisapride and fatal arrhythmia. N. Engl. J. Med., 335: 290-291 (1996).
5. SoRelle, R.: Withdrawal of Posicor from market. Circulation, 98: 831-832 (1998).
6. Krayenbühl, J. C., Vozeh, S., Kondo-Oestreicher, M. and Dayer, P.: Drug-drug interactions of new active substances: mibefradil example. Eur. J. Clin. Pharmacol., 55: 559-565 (1999).
7. Sica, D. A. and Gehr, T. W.: Rhabdomyolysis and statin therapy: relevance to the elderly. Am. J. Geriatr. Cardiol., 11: 48-55 (2002).
8. Bachmann, K. A. and Lewis, J. D.: Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants. Ann. Pharmacother., 39: 1064-1072 (2005).
9. Wienkers, L. C. and Heath, T. G.: Predicting in vivo drug interactions from in vitro drug discovery data. Nat. Rev. Drug Discov., 4: 825-833 (2005).
10. Zhou, S. F.: Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr. Drug Metab., 9: 310-322 (2008).
11. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. and Guengerich, F. P.: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 270: 414-423 (1994).
12. US FDA: Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling. Rockville, Food and Drug Administration, 2006, pp. 1-55.
13. Ueng, Y. F., Chen, C. C., Chung, Y. T., Liu, T. Y., Chang, Y. P., Lo, W. S., Murayama, N., Yamazaki, H., Souček, P., Chau, G. Y., Chi, C. W., Chen, R. M. and Li, D. T.: Mechanism-based inhibition of cytochrome P450 (CYP)2A6 by chalepensin in recombinant systems, in human liver microsomes and in mice in vivo. Br. J. Pharmacol., 163: 1250-1262 (2011).
14. Huitema, A. D., Kerbusch, T., Tibben, M. M., Rodenhuis, S. and Beijnen, J. H.: Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens. Cancer Chemother. Pharmacol., 46: 119-127 (2000).
15. Niemi, M., Backman, J. T. and Neuvonen, P. J.: Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clin. Pharmacol. Ther., 76: 239-249 (2004).
16. Galetin, A., Ito, K., Hallifax, D. and Houston, J. B.: CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. J. Pharmacol. Exp. Ther., 314: 180-190 (2005).
17. Youdim, K. A., Lyons, R., Payne, L., Jones, B. C. and Saunders, K.: An automated, high-throughput, 384 well cytochrome P450 cocktail IC50 assay using a rapid resolution LC-MS/MS end-point. J. Pharm. Biomed. Anal., 48: 92-99 (2008).
18. Ryu, J. Y., Song, I. S., Sunwoo, Y. E., Shon, J. H., Liu, K. H., Cha, I. J. and Shin, J. G.: Development of the õInje Cocktailö for high-throughput evalutation of five human cytochrome P450 isoforms in vivo. Clin. Pharmacol. Ther., 88: 275 (2010).
19. Turpault, S., Brian, W., Van Horn, R., Santoni, A., Poitiers, F., Donazzolo, Y. and Boulenc, X.: Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br. J. Clin. Pharmacol., 68: 928-935 (2009).
20. Favreau, L. V., Palamanda, J. R., Chin-chung, L. and Amin, A. N.: Improved reliability of the rapid microtiter plate assay using recombinant enzyme in predicting CYP2D6 inhibition in human liver microsomes. Drug Metab. Dispos., 27: 436-439 (1999).
21. Di, L., Kems, E. H., Li, S. Q. and Carter, G. T.: Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS. Int. J. Pharm., 335: 1-11 (2007).
22. Bell, L., Bickford, S., Nguyen, P. H., Wang, J., He, T., Zhang, B., Friche, Y., Zimmerlin, A., Urban, L. and Bojanic, D.: Evaluation of fluorescence-and mass spectrometry-based CYP inhibition assays for use in drug discovery. J. Biomol. Screen., 13: 343-353 (2008).
23. Kenworthy, K. E., Clarke, S. E., Andrews, J. and Houston, J. B.: Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab. Dispos., 29: 1644-1651 (2001).
24. US FDA: Guidance for Industry: Bioanalytical Method Validation, Rockville, Food and Drug Administration, 2001, pp. 1-22.
25. Smith, D., Sadagopan, N., Zientek, M., Reddy, A. and Cohen, L.: Analytical approaches to determine cytochrome P450 inhibitory potential of new chemical entities in drug discovery. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 850: 455-463 (2007).
26. Zhou, S., Yung, C. S., Cher, G. B., Chan, E., Duan, W., Huang, M. and McLeod, H. L.: Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet., 44: 279-304 (2005).
27. Zhou, S. F., Xue, C. C., Yu, X. Q., Li, C. and Wang, G.: Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther. Drug Monit., 29: 687-710 (2007).
28. Venkatakrishnan, K. and Obach, R. S.: Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evalution. Curr. Drug Metab., 8: 449-462 (2007).
29. Johnson, W. W.: Cytochrome P450 inactivation by pharmaceuticals and phytochemicals: therapeutic relevance. Drug Metab. Rev., 40: 101-147 (2008).